StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $16.18 | $15.94 | -1.48% | 3.3M |
| 05-12 | $16.27 | $16.76 | +3.01% | 3.3M |
| 05-13 | $16.05 | $14.69 | -8.50% | 6.9M |
| 05-14 | $14.84 | $15.25 | +2.76% | 3.8M |
| 05-15 | $15.25 | $14.55 | -4.59% | 4.7M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $216.17M | $812.03M | $519.15M | $302.31M |
Operating Income | $5.28M | $45.11M | $-43.30M | $-75.94M |
Net Income | $-510.00K | $-68.09M | $-150.04M | $-174.37M |
EPS (Diluted) | $0.00 | $-3.22 | $-4.83 | $-12.80 |
Total Assets | $1.16B | $1.13B | $984.57M | $955.06M |
Total Liabilities | $568.90M | $548.36M | $506.21M | $502.15M |
Cash & Equivalents | $819.90M | $796.27M | $753.22M | $718.93M |
Free Cash Flow OCF − CapEx | $22.53M | $66.89M | $27.20M | $-28.13M |
Shares Outstanding | 282.65M | 282.53M | 282.10M | 281.09M |
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.